Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.

Luca Gianni,Mauro Mansutti,Antonio Antón,Lourdes Calvo Martínez,Giancarlo Bisagni,Begoña Bermejo,Vladimir Semiglazov,Marc Thill,Jose Ignacio Chacon,Arlene Chan,Serafin Morales,Isabel Alvarez,Ainhara Lahuerta,Milvia Zambetti,Andrew Redfern,Rebecca Dent,Simona Barlera,Pinuccia Valagussa,Ignasi Tusquets

Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.

2019

Luca Gianni
Mauro Mansutti
Antonio Antón
Lourdes Calvo Martínez
Giancarlo Bisagni
Begoña Bermejo
Vladimir Semiglazov
Marc Thill
Jose Ignacio Chacon
Arlene Chan
Serafin Morales
Isabel Alvarez
Ainhara Lahuerta
Milvia Zambetti
Andrew Redfern
Rebecca Dent
Simona Barlera
Pinuccia Valagussa
Ignasi Tusquets

515Background: The ETNA study showed that substituting P with nab-P did not significantly increase the overall rate of pathological complete response (pCR) (P 18.6%, nab-P 22.5%, p = 0.19). The mul...

Keywords:

HER2 negative
Survival analysis
Nab-paclitaxel
Paclitaxel
Anthracycline
Breast cancer
Oncology
Pathology
Internal medicine
Medicine
complete response
Pathological
event free survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations